A double blind, randomised, placebo controlled study investigating the efficacy of roflumilast in reducing number of acute events in patients with chronic fibrotic sarcoidosis

Trial Profile

A double blind, randomised, placebo controlled study investigating the efficacy of roflumilast in reducing number of acute events in patients with chronic fibrotic sarcoidosis

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Sarcoidosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top